Thomas J. Herzfeld Advisors, Inc. Abb Vie Inc. Transaction History

Thomas J. Herzfeld Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $1,857 - $2,169	12 New	12 $2.06 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $96,451 - $111,657	722 New	722 $108 Million
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $1,987 - $2,473	15 Added 2.12%	722 $97,000
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $414 - $497	3 Added 0.43%	707 $114,000
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $659 - $818	5 Added 0.72%	704 $114,000
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $61,380 - $67,572	600 Added 606.06%	699 $76,000
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $965 - $1,304	12 Added 13.79%	99 $11,000
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $1,030 - $1,209	12 Added 16.0%	87 $7,000
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $5,502 - $7,363	75 New	75 $7,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Thomas J. Herzfeld Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Thomas J. Herzfeld Advisors, Inc. with notifications on news.